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Ncwcemcrx rind nan-rpcciali%ts would be Ml advired to 
initinrrc thcmsclves by first readinlil Chapter 6, written by the 
ISliter and entitled ‘Searching Through Scqucncc Datsbescs’, 
Shir delicribcn succinctly, with the hid of ndve~al illuztrrrtivct 
prtlctisal cxamplc~, how proper intcrprrtarion of the 
computer datn requires the investigator ‘to think like a 
%riologi#t, and not a statistician’. 
Section I, 811 Databases, provides dctnilcd dcxcriptions of 
the organization and availability to the scientific community 
of the information compiled in various Data Banks, It 
includes a Table which lists datnbascs for miscellaneous 
biological I~RcPo~~oIc~~~~J, fogclher with addresses to the 
source of each> An additional extrcmcly valutiblc fcaturc is the 
agreement ot’all contributing authors to make their computer 
groarams available on rcqucrt at only the cost of the tapes (or 
diskcItes) and shipping. 
Farrirulady Intemtln~ 18, rlrh rcvlcwrr la Stctlon IV on 
prcdistlan of RNA ntelznrlnry @Ed ttrtlury) JOPLICIW~O~ t’rem 
~F~U~REF, Bat&. Thrrc 1~ no unalsgous xcrctian an p~crln 
%tructurgs. Wut this ir perrially csmgonrrtoFt tar by rhc final 
Chag%or 42 on Phylaprrn~tle fWationxhipx t’rot~ Phrrc- 
Dim*n&mal Protein Strurtured, which dernUnstratcX that 
trees unobtainakld from xequcncc somparisonx rlone may In 
some instances rho derived from structural ~~~~~ri~on~, The 
authsn point out that thix i.s due to the fact that wtrucrural 
data contain much more information per protein molecule 
rhrrn scqurncc tinta. Reference in made to about 48(r Iitructurea 
tlaponitcd in the Rraakhuvcn Pretcin Data Bank, far lexs than 
rhi: number 0r aquenccx availnbl~ But the number ix 
increasing at A rclrtively rapid rate, parlitularly for 
pclypaptitlcs whh melrculnr masses n@t exceeding XI-23 kDa1 
far which Wueturen may now be assigned wifhout 
erynrnlliztrtion with the aid of two-dimenlrionnl NMA 
reehniqucs. Actually the July 1990 Ncwslcttcr of the Protein 
Datrr Bank includes coordinate entries far more than SSQ 
proteins, with mnny more in proerds of cnmplctian. 
This volume is both timely and very well up&cd. 
Published in 1990, it contains numerous references to the 1989 
liternturc, including a number’ ‘in I)rcss’ which will appear in 
1990. Both the Author and Subject lndexrs are exhaustive. 
This is not only an essential book for libraries, but, despite the 
price, well worrh having at one’s disposal in the laboratory... 
or beside the computer. 
David Shugar 
Wibowomes and Protein Synthesis, A Prnctical Approach; Edited by G, Spedding; Oxford University Press; 
Oxford, 1990; xxiv -t- 318 pages; f22,SO 
This recent volume in the Practical Awroach Series is many of the techniques used successfully for so many years 
have evolved with the times and have been complemented 
fruitfully with more modern approaches including, as 
examples, gene cloning and the development of exquisite 
physical methods for probing ribosome structure and 
architecture, Significant advances in the majority of research 
fields are very frequently dependent upon the development of 
new experimental techniques and this point comes over well in 
the text. Inevitably, not all areas are coveeed in detail. As 
examples there might have been, perhaps, more detailed 
coverage on antibiotics, affinity labels, antibodies, eukaryotic 
cell-free protein synthesis and HPLC - topics considered 
somewhat too briefly in the text. On balance, nevertheless, the 
Editor has done a first-class job in compiling a series of 
relevant articles ome of whish generate the current ffavour of 
excitement evident in ribosome research. After all it is no 
mean feat to make methodology per se even remotely 
interesting. 
intended as &n up-to-date guide fo rhc ‘iide sclcction of 
experimental techniques currently being employed to study 
protein synthesis, with particular reference to probing 
structure-function relationships in ribosomes. Interest in 
ribosome research has recently revived, after a somewhat 
latent period, largely as a result of the discovery of RNA 
enzymes and the development of cloning and sequencing 
techniques for studying ribosomal RNA. The volun~ is. 
therefore, timely in its publication. Certainly it includes many 
well-presented articles contributed by a large selection of 
distinguished scientists and the volume will provide a useful 
addition to the libraries of those interested in this area of 
Biochemistry overall. There are 13 major chapters covering a 
variety of topics including, amongst others, ribosrsrne 
structure a.nd reconstitution, site-directed mutagenesis of 
ribosoma! RNA anmd mechanistic aspects of protein 
synthesis. Experimental protocols are usually described with 
clarity and precision and their repetition in the laboratory 
should be feasible in most cases. It is refreshing to see how Michael Cannon 
Protein niad Pharmaceutical Engineering (UCLA Synnposia ocn Moleculas wrnd CeMsr lDiobgy New Series, Vol. 
IW; Edited by Ckarles S. Craik, Robert Flstterick, C. Robert Matthews and Janus Wells; Wiley-Liss; New 
York, 1990; xiv + 184 pages; $59.50 
This publication has resulted from the 1989 Upjohn-UCLA contains 12 Chapters, written by selected participants at the 
Symposium on Protein and Pharmaceutical Engineering. It meeting. There is a strong bias towards Protein Engineering 
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TM wclcomc ut~late on the AIDS research situation nut 
tugcther for &A by W.J.W. Morrow of ID&C 
Pharmaceuticals rnkcs the form of a series of 6 papers from 
leading groups covering the currcnc clinical and social 
situation, all aspects of the HIV infection and life cycle 
pracess, the inmune response to the virus and recent attempts 
at vaccine development. In 19118, a set of AlBS reviews was 
published in Scientific American. At that time author’s views, 
which no doubt reflected the collective feelings in the scientific 
community, were essentially upbeat and optimistic, The 
massive research effort urrdcrway would in the end prevail. 
After all this was not anything as intractable as cancer; merciy 
an infectious disease with a clearly defined and cultureable 
agent. This assurance was bolstered by the detailed knowlcdgc 
then uncovered of the virus structure, genetic and physical, 
and its life cycle, Many of the early questions had been 
answered and on the basis of evidence available plausible 
hypotheses had been advanced for the rest. 
The feeling pervading this BBA issue is more uncertain and 
pessimistic. Depressingly little movement towards a cure can 
be detected in the intervening period. In addition, many of 
those assumptions about the way HlVs 1 and 2 go about their 
fatal business have not been validated, In fact several have 
been partially undermined. 
Take the straight forward notion that the AIDS condition 
is caused by I-iIV attacking and destroying the CD4-bearing T- 
helper lymphocytes, a view fostered by the experimentally 
verified fact that the virus binds to and infects any cell 
sporting these receptor molecules at their surface via a direct 
interaction with CD4. However, as discussed in Sattentau’s 
article, although the population of T-helper cells declines 
during the course of the disease, very few in fact carry the 
virus. Also, cells which do not make CD4 are now known to 
be infected. Mow does HIV get into these? Kieber-Emmons, 
Jarneson and Marrow in their review on the role of the 
gp120-CD4 interface report that mutations can be inserted 
into the viral coat protein which do not affect its ability to 
bind to CD4 but which do destroy virus infectivity, Does HIV 
therefore have a second cell surface ligand and is this more 
important for the net p;rthologicnl effect? These new 
questions arechallenging thr old dogmn and the picture is ICSS 
certain than before. 
The fact that patients die because they cannot defend 
themselves nyainst secondary infections is obvious. But is this 
only due to the lack of an adequate number of T-helper cells? 
In their paper, Evans and Levy describe evidence which 
demonstrates a reduced ability of circulating natural killer 
cells and of aberrant functioning of phngocytic cells in AIDS 
patients, Volbcrding and McCutchnn in their stimulating 
ovcrvicw of medical aspects which introduces the series 
describe data indicating that the opportunistic infection to 
which patients are susceptible very much depends upon the 
original route of infection with HIV - astranyc finding if only 
T-helper cells are involved. 
Perhaps the least glooniy of the collection is the paper by 
Kieber-Emmons et al. dealing with the structural, 
immunological and pathological facts relating to virus- 
receptor interaction. Here there have been important 
developments. Soluble CD4, which is the extracellular portion 
of this membrane glycoprotein, has been shown to inhibit 
viral infection in vitro. When tested in vivo however it was 
quickly cleared from the blood stream. Genetic manipulation 
was applied to the problem and a soluble 
CD4-immunoglobulin heavy chain chimera was produced. 
This survives for much longer in the circulation of patients 
and is currently under clinical trial. The results are eagerly 
awaited for this test will reveal whether or not the currently 
held image of the disease has feet of clay. If HIV pathology 
is really mediated by an alternative and as yet unknown cell 
surface receptor, then soluble CD4 will have little effect on the 
progress of AIDS in patients. 
One serious difference between this and the earlier series is 
the presence of an article in the latter on available drugs and 
strategies for the develogmsnc of new ones to interfere with 
viral reproduction and sprebd. In the BBA collection there are 
only 2 paragraphs on chemotherapeutic aspects and only AZT 
is mentioned. This is sureIy a major omission, difficult to 
understand in light of the readable vaccine review by Zhou 
